Rankings
▼
Calendar
DNLI Q4 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q4 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$126M
Gross Profit
$126M
100.0% margin
Operating Income
$75M
59.5% margin
Net Income
$78M
61.7% margin
EPS (Diluted)
$0.79
QoQ Revenue Growth
+10416.8%
Cash Flow
Operating Cash Flow
$93M
Free Cash Flow
$92M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$662M
Total Liabilities
$115M
Stockholders' Equity
$547M
Cash & Equivalents
$77M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$126M
$0
—
Gross Profit
$126M
$0
—
Operating Income
$75M
-$24M
+417.4%
Net Income
$78M
-$23M
+438.8%
← FY 2018
All Quarters
Q1 2019 →